GlycoMimetics, Karyopharm Join Biotech IPO Queue


Oct 08, 2013

Two more biotechs are hoping to raise substantial funds for their R&D work while investors remain interested in the potential rewards of drug development.

So far this year 38 biotechs have gone public raising $2.8 billion.

Karyopharm Therapeutics, a clinical-stage pharmaceutical company, is focused on its lead anticancer contender, Selinexor. GlycoMimetics, has completed a mid-stage trial of its lead therapy, GMI-1070, which is aimed at rare cases of vaso-occlusive crisis triggered by sickle cell disease. Read more

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments